Amgen Inc. (NASDAQ:AMGN).
On August 26 analysts at Gabelli & Co. starting coverage on AMGN setting a rating of “Hold”. Bernstein released its first research report on the stock by announcing an initial rating of “Market Perform”.
On April 5, 2016 BMO Capital began coverage with an initial rating of “Outperform” and projecting a price target of $183.00. Equity analyst Citigroup starting coverage on the stock giving it an initial rating of “Neutral”.
February 8 investment analysts at Argus Research made no change to the company rating of “Buy” but lowered the price expectation from $202.00 to $185.00.
In the market the company is trading up by 0.01% since yesterday’s close of $171.63. Amgen Inc. also recently declared a dividend which was paid on Thursday September 8th, 2016. The dividend payment was $1.000 per share for the quarter or $4.00 on an annualized basis. This dividend represents a yield of $2.29. The ex-dividend date was set for Monday the 15th of August 2016.
Company chares are trading at $171.64 a tad under the 50 day moving average which is $172.07 and marginally over the 200 day moving average of $160.76. The 50 day moving average moved down $-0.44 and the 200 day average went up by +6.76%.
The P/E ratio is currently 17.56 and market capitalization is 128.44B. As of the latest earnings report the EPS was $9.77 and is projected to be $11.36 for the current year with 748,360,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $2.82 and the next full year EPS is projected to be $12.47.
Short traders are more bearish on shares of the company recently as shown by the increase in short interest. The company experienced a rise in short interest of 0.09% as of September 15, 2016 from the last reporting period. Short shares increased from 8,005,185 to 8,720,839 over that timeframe. With short interest at 8,720,839 and short average daily volume at 2,699,005, the short-interest ratio is 3.2 and the short interest percentage is 0.01% as of September 15.